Advanced Liver Cancer Treatment Comparison Study
Part of Cancer, Digestive system clinical trials.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of hepatocellular carcinoma (liver cancer) or cirrhosis with typical HCC features on imaging
- Age 18 or older in good overall health (able to perform normal daily activities)
- Advanced stage liver cancer that cannot be surgically removed, with tumors in both sides of the liver
- No prior chemotherapy, immunotherapy, or interventional liver procedures
- Good liver function (Child-Pugh Grade A) with normal blood counts and kidney function
- No cancer spread outside the liver, no portal vein blockage, and no active bleeding risk
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This study tests two different treatment combinations for liver cancer that cannot be removed with surgery. One group gets a treatment called TACE plus a pill combination, and the other gets TACE plus standard targeted immunotherapy. The goal is to see which approach works better.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.